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Abstract. Nanoparticle albumin-bound (nab)-paclitaxel 
appears to exhibit better response rates in patients with meta-
static urothelial cancer of the bladder whom are pretreated 
with nab-paclitaxel compared with conventional paclitaxel. 
Paclitaxel may induce multidrug resistance in patients with 
cancer, while the mechanisms of resistance against paclitaxel 
are manifold. These include reduced function of pro-apoptotic 
proteins, mutations of tubulin and overexpression of the drug 
transporter adenosine 5'-triphosphate-binding cassette trans-
porter subfamily B, member 1 (ABCB1). To evaluate the role 
of ABCB1 in nab-paclitaxel resistance in urothelial cancer 
cells, the bladder cancer cell lines T24 and TCC-SUP, as well 
as sub-lines with acquired resistance against gemcitabine 
(T24rGEMCI20 and TCC-SUPrGEMCI20) and vinblastine 
(T24rVBL20 and TCC-SUPrVBL20) were examined. For the 
functional inhibition of ABCB1, multi-tyrosine kinase inhibi-
tors with ABCB1-inhibiting properties, including cabozantinib 
and crizotinib, were used. Additional functional assessment 
was performed with cell lines stably transduced with a lenti-
viral vector encoding for ABCB1, and protein expression was 
determined by western blotting. It was indicated that cell lines RYHUH[SUHVVLQJ$%&%H[KLELWHGVLPLODUUHVLVWDQFHSURÀOHV
to nab-paclitaxel and paclitaxel. Cabozantinib and crizotinib 
sensitized tumor cells to nab-paclitaxel and paclitaxel in the 
same dose-dependent manner in cell lines overexpressing 
ABCB1, without altering the downstream signaling of tyro-
sine kinases. These results suggest that the overexpression 
of ABCB1 confers resistance to nab-paclitaxel in urothelial 
cancer cells. Additionally, small molecules may overcome 
resistance to anticancer drugs that are substrates of ABCB1.
Introduction
Patients with locally advanced or metastatic urothelial cancer 
of the bladder exhibit poor prognoses, with an overall survival RIPRQWKVVXEVHTXHQWWRÀUVWOLQHFKHPRWKHUDS\ZLWKWKH
combination of gemcitabine and cisplatin as standard of care. 
Treatment failure is commonly caused by resistance acquisi-
tion to chemotherapy subsequent to the primary response (1,2).,Q(XURSHYLQÁXQLQH LV WKHRQO\DSSURYHGVHFRQGOLQH
chemotherapy, with only moderate response rates (3). 
There is currently no USA Food and Drug Administration 
(FDA)-approved treatment subsequent to first-line chemo-
therapy in the USA. However, taxanes are commonly used for 
palliative chemotherapy based on modest response rates in 
several small, nonrandomized phase II trials (4).
Nanoparticle albumin-bound (nab)-paclitaxel, also termed 
Abraxane®, is already widely used in the clinical treatment 
of breast cancer with FDA approval in 2005, non-small cell 
lung cancer (NSCLC) with FDA approval in 2010 and pancre-
atic cancer with FDA approval in 2013 (5,6). Nab-paclitaxel 
achieved a marked overall response rate of 27.7% in patients 
with metastatic urothelial cancer of the bladder who were 
pretreated with cisplatin, and may be more effective than 
conventional paclitaxel (7). At present, a randomized phase 
II trial [National Clinical Trials (NCT) no., 02033993] 
comparing nab-paclitaxel and paclitaxel is ongoing.,WKDVEHHQSRVWXODWHGWKDWWKHLQFUHDVHGHIÀFDF\RIQDESDFOL-
taxel compared with that of paclitaxel is based on an increased 
transendothelial glycoprotein (gp)60-mediated transport and 
enhanced intratumoral accumulation as a result of the secreted 
protein acidic and rich in cysteine (SPARC)-albumin interac-
tion (5,8,9). Dong et al (10) demonstrated that paclitaxel-loaded 
lipid-based nanoparticles containing the Brij 78 surfactant 
may overcome adenosine 5'-triphosphate-binding cassette 
transporter subfamily B, member 1 (ABCB1)-mediated 
drug resistance. By contrast, other studies hypothesized 
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that resistance to nanoparticle-bound paclitaxel may also be 
ABCB1 mediated (11,12). However, it remains unclear whether 
albumin-bound paclitaxel nanoparticles may overcome drug 
resistance caused by ABCB1 (5).
The present study evaluated whether ABCB1 transporters 
affect the antitumoral activity of nab-paclitaxel in a panel 
of urothelial cancer cell lines. The results demonstrate that 
ABCB1 overexpression mediates resistance to nab-paclitaxel. 
Resistance to nab-paclitaxel may be overcome by inhibitors of 
ABCB1 transporters, including cabozantinib and crizotinib, 
two FDA-approved small molecule inhibitors being tested at 
present as second-line therapy for urothelial carcinoma (NCT 
nos., 02612194, 01688999 and 02496208).
Materials and methods
Drugs. Cisplatin was purchased from Gry-Pharma GmbH 
(Dresden, Germany), gemcitabine from Lilly Germany GmbH 
(Bad Homburg, Germany), paclitaxel from Bristol-Myers 
Squibb (New York, NY, USA), vinblastine from Teva Pharma-
ceutical Industries Ltd., (Petah Tikva, Israel), and cabozantinib 
and crizotinib from Selleck Chemicals (Houston, TX, USA). 
Nab-paclitaxel was purchased from Celgene International %RXGU\6ZLW]HUODQGDQGZDVVWRUHGDWÝ&VXEVHTXHQWWR
preparation.
Cell lines and lentiviral transduction. The urothelial bladder 
cancer T24 and TCC-SUP cell lines were obtained from the 
American Type Culture Collection (Manassas, VA, USA). 
Drug-resistant sublines were established by continuous exposure 
to increasing drug concentrations as described previously (13) 
and are part of the Resistant Cancer Cell Line collection 
(Institute of Medical Virology, University Hospital Frankfurt, 
Frankfurt, Germany): T24rGEMCI20 (gemcitabine-resistant, 
20 ng gemcitabine/ml), T24rVBL20 (vinblastine-resistant, 20 ng 
vinblastine/ml), TCC-SUPrGEMCI20 and TCC-SUPrVBL20 
(vinblastine-resistant, 20 ng vinblastine/ml).
The cell lines TCC-SUPABCB1 and T24ABCB1 with ectopic 
overexpression of ABCB1 (University Medical Center 
Hamburg-Eppendorf, Hamburg, Germany), and the corre-
sponding control cell lines with empty vector TCC-SUPCER2 
and T24CER2 (University Medical Center Hamburg-Eppen-
dorf), were established by lentiviral transduction using the 




medium supplemented with 10% fetal calf serum (Gibco; 7KHUPR)LVKHU6FLHQWLÀF,QF:DOWKDP0$86$&HOOOLQHDXWKHQWLFDWLRQZDVSHUIRUPHGE\VKRUWWDQGHPUHSHDWSURÀOLQJ
Cell viability assay. Cell viability was determined by the MTT 
dye reduction assay after 120 h of incubation, as described 
previously (13). Drug resistance was determined according to UHVLVWDQFHIDFWRUVGHÀQHGDVhalf maximal inhibitory concen-
tration (IC50) drug in resistant cells/IC50 drug in parental cells. 
The cell lines were considered to be resistant to a drug if 
the resistance factor was >2 (16). Sensitization to a drug was GHWHUPLQHGDFFRUGLQJWRVHQVLWL]DWLRQIDFWRUVGHÀQHGDV,&50 
drug in the tested cell line without tyrosine kinase inhibitor 
(TKI)/IC50 drug in the tested cell line plus TKI. To evaluate 
the in vitroVWDELOLW\RIQDESDFOLWD[HOHIÀFDF\IDFWRUVZHUH
defined as IC50 of 7 or 28 days-old nab-paclitaxel/IC50 of 
freshly prepared nab-paclitaxel.
Western blotting. Cells were lysed on ice in Triton X-100 VDPSOHEXIIHUFHQWULIXJHGDWÝ&DW[g for 5 min, DQGVXSHUQDWDQWZDVVWRUHGDWÝ&3URWHLQFRQFHQWUDWLRQ
was determined using BioRad DC protein assay (catalog 
no. 5000112, Bio-Rad Laboratories, Inc., Hercules, CA, USA), 
and the proteins (concentration 1 mg/ml; 15 µl per lane) were 
separated by 12% SDS-PAGE. Proteins were transferred 
onto nitrocellulose membrane (catalog no. 88,018; Thermo )LVKHU6FLHQWLÀF ,QFDQGEORFNHGZLWKERYLQHVHUXP
albumin (Carl Roth, Karlsruhe, Germany) in Tris buffered 
saline containing 0.05% (v/v) Tween®-20 (Sigma-Aldrich; 
Merck KGaA, Darmstadt, Germany) for 40 min at room WHPSHUDWXUH0HPEUDQHVZHUH LQFXEDWHGRYHUQLJKWDWÝ&
with specific primary antibodies against ơ-actin (1:1,000; 
catalog no. A2228; Sigma-Aldrich; Merck KGaA), protein 
kinase B (Akt; 1:1,000; catalog no. 9272; Cell Signaling Tech-
nology, Inc., Danvers, MA, USA) and phosphorylated (p)-Akt 
(T308; 1:1,000; catalog no. 2965; Cell Signaling Technology). 
Membranes were washed in Tris buffered saline containing 
0.05% (v/v) Tween®20 (Sigma-Aldrich; Merck KGaA) for 
40 min at room temperature, blocked and incubated for 1 h 
with fluorescence-labeled secondary antibodies IRDye 
800CW goat anti-rabbit immunoglobulin G (IgG; heavy and 
light chains; 1:20,000; catalog no. 926-32211; LI-COR Biosci-
ences, Lincoln, NE, USA) and IRDye 800CW goat anti-mouse 
IgG (heavy and light chains; 1:20,000; catalog no. 926-32210; 
LI-COR Biosciences) at room temperature. Fluorescence of 
the secondary antibody was measured with the Odyssey CLx 
Imaging system and the Image Studio software (version 3.1; 
LI-COR Biosciences).
Statistical analysis. For statistical analyses, unpaired Student's 
t-test, analysis of variance and Student-Newman-Keuls test were 
performed for comparison of IC50 values following treatment of 
tumor cell lines with various anti-cancer compounds. Statistical 
analyses were performed with GraphPad Prism® (Version 
5.0c; GraphPad Software Inc., La Jolla, CA, USA). P<0.05 was FRQVLGHUHGWRLQGLFDWHDVWDWLVWLFDOO\VLJQLÀFDQWGLIIHUHQFH
Results
In vitro stability studies of nab-paclitaxel. As the instability of 
nab-paclitaxel has been examined previously in vivo (17), The 
present study sought to evaluate for how long freshly prepared 
nab-paclitaxel may be used in vitro. Therefore, functional 
MTT assays were conducted with nab-paclitaxel on days 0, 7, 
and 28 subsequent to drug preparation. A slight loss of the anti-WXPRUDOHIÀFDF\RIQDESDFOLWD[HODIWHUGD\VZDVREVHUYHGZLWKHIÀFDF\IDFWRUVRIHIÀFDF\IDFWRURIGD\ ,&50 
at day 7/IC50 at day 0) compared with that revealed by MTT 
assays at day 0. On day 28, a marked loss of antitumoral HIÀFDF\ZLWKHIÀFDF\IDFWRUVRIHIÀFDF\IDFWRURIGD\ ,&50 day at 28/IC50 at day 0) was observed (Fig. 1). A VLJQLÀFDQWWLPHGHSHQGHQWORVVRIHIÀFDF\RIQDESDFOLWD[HO
was also observed. Therefore, nab-paclitaxel was used only on 
the day of preparation for additional experiments.
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Cell viability assays. 7KHUHZDVQRVLJQLÀFDQWGLIIHUHQFH
between the antitumoral activity of nab-paclitaxel and 
paclitaxel in chemosensitive urothelial cancer cells or their 
chemoresistant sublines (Tables I-IV). The ABCB1-over-
expressing cell lines were similarly resistant to these 
two compounds. Cabozantinib and crizotinib sensitized 
the ABCB1-overexpressing tumor cell lines T24rVBL20, 
T24ABCB1, TCC-SUP rGEMCI20, TCC-SUP rVBL20 and 
TCC-SUPABCB1 (18) to nab-paclitaxel and paclitaxel in a 
dose-dependent manner (Tables I-IV). In addition, cabo-
zantinib sensitized these ABCB1-overexpressing tumor cell 
lines to vinblastine therapy in a dose-dependent manner 
(Tables I and III). The IC50 values of cabozantinib and 
crizotinib monotherapy were in the low-micromolar range. 
Resistance against gemcitabine, vinblastine or stable trans-
duction with a lentiviral vector encoding for ABCB1 did QRWDSSHDUWRVLJQLÀFDQWO\FKDQJHWKHVHQVLWLYLW\SURÀOHVWR
cabozantinib or crizotinib (Table V).
Table I. IC50 values of paclitaxel, nab-paclitaxel, gemcitabine and vinblastine in TCC-SUP, TCC-SUP
rGEMCI20, TCC-SUPrVBL20, 
TCC-SUPCER2 and TCC-SUPABCB1 cells in the presence of cabozantinib.
 IC50 (sensitization factor)
a, ng/ml
 ----------------------------------------------------------------------------------------------------------------------------------------------------
Cell line Cabozantinib, µM Paclitaxel Nab-paclitaxel Gemcitabine Vinblastine
TCC-SUP 0 1.14±0.12 0.78±0.34 1.20±0.39 0.36±0.14
TCC-SUP 0.5 1.07±0.07 (1.07) 0.93±0.31 (0.84) 0.92±0.01 (1.3) 0.47±0.02 (0.77)
TCC-SUP 1.25 1.18±0.14 (0.97) 0.79±0.14 (0.99) 2.27±0.30 (0.53) 0.31±0.16 (1.16)
TCC-SUPrGEMCI20 0 4.98±1.50 0.69±0.45 42.56±0.90 0.69±0.23
TCC-SUPrGEMCI20 0.5 2.01±0.35 (2.48) 0.56±0.15 (1.23) 37.72±0.60 (1.13) 0.60±0.07 (1.15)
TCC-SUPrGEMCI20 1.25 1.23±0.36 (4.05) 0.31±0.17 (2.22) 43.40±13.60 (0.98) 0.35±0.07 (1.97)
TCC-SUPrVBL20 0 159.60±24.50 395.40±65.80 1.24±0.30 35.29±6.50
TCC-SUPrVBL20 0.5 66.33±13.50 (2.41) 79.52±6.90 (4.97) 1.19±0.40 (1.04) 8.19±1.16 (4.31)
TCC-SUPrVBL20 1.25 20.86±3.90 (7.65) 22.64±1.90 (17.46) 1.92±0.21 (0.65) 3.44±0.69 (10.26)
TCC-SUPCER2 0 1.96±0.44 2.43±0.25 1.84±0.18 0.43±0.19
TCC-SUPCER2 0.5 1.88±0.58 (1.04) 2.11±0.23 (1.15) 1.71±0.11 (1.08) 0.58±0.09 (0.74)
TCC-SUPCER2 1.25 1.42±0.42 (1.38) 1.77±0.26 (1.37) 1.57±0.02 (1.17) 0.31±0.14 (1.39)
TCC-SUPABCB1 0 93.14±18.40 140.0±91.30 1.46±0.22 11.33±3.70
TCC-SUPABCB1 0.5 19.12±7.10 (4.87) 25.96±17.30 (5.39) 1.53±0.01 (0.95) 2.00±0.83 (5.67)
TCC-SUPABCB1 1.25 7.81±1.60 (11.93) 5.03±2.50 (27.83) 1.61±0.23 (0.91) 0.87±0.35 (13.06)
a6HQVLWL]DWLRQIDFWRU ,&50 of the drug in the tested cell line without cabozantinib/IC50 of the drug in the tested cell line plus cabozantinib. Values 
are means ± standard deviations. IC50, half maximal inhibitory concentration; nab, nanoparticle albumin-bound.
Figure 1. In vitro stability of nab-paclitaxel. IC50 values of MTT assays with nab-paclitaxel on days 0, 7 and 28 in T24, T24
rGEMCI20, T24rVBL20, T24CER2 
and T24ABCB1 cells. Values are means ± standard deviations of at least three independent experiments. Nab, nanoparticle albumin-bound; IC50, half maximal 
inhibitory concentration.
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Western blot analysis. Akt is a well-known downstream marker 
of the tyrosine-protein kinase Met (c-MET) and vascular 
endothelial growth factor receptor 2 inhibitor cabozantinib, 
and of the anaplastic lymphoma kinase, hepatocyte growth 
Table III. IC50 values of paclitaxel, nab-paclitaxel, gemcitabine and vinblastine in T24, T24
rGEMCI20, T24rVBL20, T24CER2 and 
T24ABCB1 cell viability in the presence of cabozantinib.
 IC50 (sensitization factor)
a, ng/ml
 ---------------------------------------------------------------------------------------------------------------------------------------------------------------
Cell line Cabozantinib, µM Paclitaxel Nab-paclitaxel Gemcitabine Vinblastine
T24 0 5.48±1.15 4.65±0.75 3.60±0.80 0.62±0.16
T24 0.5 4.89±0.52 (1.12) 4.78±0.85 (0.97) 3.10±0.04 (1.16) 0.73±0.16 (0.85)
T24 1.25 5.05±0.88 (1.09) 3.87±0.32 (1.20) 6.40±0.24 (0.56) 0.60±0.11 (1.03)
T24rGEMCI20 0 7.05±0.90 8.36±0.50 54.28±1.60 0.56±0.22
T24rGEMCI20 0.5 4.49±0.52 (1.57) 4.76±0.60 (1.76) 56.37±0.90 (0.96) 0.67±0.05 (0.84)
T24rGEMCI20 1.25 4.22±0.35 (1.67) 4.09±0.20 (2.04) 78.48±0.40 (0.69) 0.47±0.11 (1.19)
T24rVBL20 0 576.00±81.50 1,174.00±278.00 1.31±0.50 117.28±13.00
T24rVBL20 0.5 155.20±49.90 (3.70) 257.50±48.20 (4.56) 1.20±0.05 (1.09) 32.86±2.19 (3.57)
T24rVBL20 1.25 61.99±3.90 (9.29) 72.76±7.10 (16.14) 2.30±0.15(0.60) 9.44±1.09 (12.42)
T24CER2 0 4.68±1.60 7.28±1.97 4.90±1.60 0.67±0.29
T24CER2 0.5 4.54±1.50 (1.36) 6.52±1.76 (1.12) 3.40±0.06 (1.44) 0.93±0.35 (0.72)
T24CER2 1.25 3.34±0.50 (1.40) 5.04±1.17 (1.44) 6.40±0.09 (0.77) 0.52±0.12 (1.29)
T24ABCB1 0 105.80±28.70 139.30±27.10 3.30±2.50 11.62±1.37
T24ABCB1 0.5 26.15±4.80 (4.05) 32.30±3.95 (4.31) 3.10±0.07 (1.06) 6.99±1.20 (1.66)
T24ABCB1 1.25 8.97±2.01 (11.97) 12.80±2.58 (10.88) 3.80±0.16 (0.87) 5.54±0.89 (2.10)
a6HQVLWL]DWLRQIDFWRU ,&50 of the drug in the tested cell line without crizotinib/IC50 of the drug in the tested cell line plus crizotinib. Values are 
means ± standard deviations. IC50, half maximal inhibitory concentration; nab, nanoparticle albumin-bound.
Table II. IC50 values of paclitaxel, nab-paclitaxel, gemcitabine and vinblastine in TCC-SUP, TCC-SUP
rGEMCI20, TCC-SUPrVBL20, 
TCC-SUPCER2 and TCC-SUPABCB1 cells in the presence of crizotinib.
 IC50 (sensitization factor)
a, ng/ml
 ------------------------------------------------------------------------------------------------------------------------------------------------------------
Cell line Crizotinib, µM Paclitaxel Nab-paclitaxel Gemcitabine Vinblastine
TCC-SUP 0 0.95±0.21 0.60±0.22 0.72±0.14 0.43±0.08
TCC-SUP 0.5 0.79±0.18 (1.20) 0.47±0.10 (1.28) 0.76±0.04 (0.95) 0.52±0.13 (0.83)
TCC-SUP 1.25 0.51±0.09 (1.86) 0.36±0.07 (1.67) 1.11±0.80 (0.65) 4.94±2.61 (0.09)
TCC-SUPrGEMCI20 0 4.40±1.86 0.94±0.85 39.98±7.20 1.00±0.38
TCC-SUPrGEMCI20 0.5 1.19±0.25 (3.70) 0.35±0.05 (2.69) 45.20±3.14 (0.88) 0.47±0.22 (2.13)
TCC-SUPrGEMCI20 1.25 0.29±0.03 (15.17) 0.39±0.13 (2.41) 41.50±36.30 (0.96) 0.63±0.40 (1.59)
TCC-SUPrVBL20 0 150.20±35.10 358.17±81.70 1.34±0.14 35.07±9.20
TCC-SUPrVBL20 0.5 90.38±37.60 (1.66) 210.67±19.94 (1.70) 1.23±0.08 (1.09) 17.98±0.72 (1.95)
TCC-SUPrVBL20 1.25 40.81±38.10 (3.68) 62.16±18.23 (5.76) 1.46±0.15 (0.92) 5.40±3.53 (6.49)
TCC-SUPCER2 0 2.00±0.61 2.11±0.56 2.02±0.13 0.53±0.14
TCC-SUPCER2 0.5 1.42±0.18 (1.41) 1.25±0.31 (1.69) 1.90±0.13 (1.06) 0.47±0.20 (1.13)
TCC-SUPCER2 1.25 0.89±0.80 (2.25) 0.39±0.16 (5.41) 2.06±1.40 (0.98) 0.46±0.13 (1.15)
TCC-SUPABCB1 0 73.44±19.60 125.49±71.00 1.76±0.20 12.73±3.90
TCC-SUPABCB1 0.5 51.36±10.80 (1.43) 74.63±39.48 (1.68) 1.47±0.06 (1.20) 8.71±3.87 (1.46)
TCC-SUPABCB1 1.25 58.64±9.40 (1.25) 40.85±8.17 (3.07) 1.79±0.32 (0.98) 15.27±3.42 (0.83) 
a6HQVLWL]DWLRQIDFWRU ,&50 of the drug in the tested cell line without crizotinib/IC50 of the drug in the tested cell line plus crizotinib. Values are 
means ± standard deviations. IC50, half maximal inhibitory concentration; nab, nanoparticle albumin-bound.
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factor receptor (MET) and proto-oncogene tyrosine-protein 
kinase ROS inhibitor crizotinib (19,20). Therefore, differences 
in Akt/pAkt expression subsequent to TKI treatment were HYDOXDWHG7KHUHZHUHQRVLJQLÀFDQWGLIIHUHQFHVLQWKHEDVDO
expression of Akt or pAkt (T308) observed in TCC-SUP, 
TCC-SUPrGEMCI20, TCC-SUPrVBL20, TCC-SUPCER2 or 
TCC-SUPABCB1 cells. In addition, treatment with 5 µM cabo-
zantinib or 2.5 µM crizotinib did not appear to affect Akt or 
pAkt (T308) expression (Fig. 2).
Discussion
Acquired taxane resistance is considered to be mediated by 
multiple mechanisms, including overexpression of drug pumps 
such as ABCB1, variations in tubulin structure, altered signal 
transduction and apoptotic pathways (21). One of the most 
important factors for taxane chemoresistance appears to be 
ABCB1 overexpression, which has been frequently detected 
subsequent to the administration of taxanes (22). Conventional 
paclitaxel is usually solved in a Cremophor® EL/ethanol vehicle, 
due to the very low aqueous solubility of the compound, which 
may cause severe anaphylactic reactions (23-25).
Nab-paclitaxel is a colloidal suspension of 130-nm 
particles homogenized in albumin and bound to pacli-
taxel (26). The superior antitumor activity of nab-paclitaxel 
compared with that of paclitaxel was demonstrated to be 
caused by increased transendothelial gp60-mediated trans-
port and increased intratumoral accumulation as a result 
of the SPARC-albumin interaction (5,8,9). Zhang et al (23) 
revealed that paclitaxel-relapsed tumors are responsive to 
nab-paclitaxel treatment, and Dong et al (10) demonstrated 
that paclitaxel-loaded lipid-based nanoparticles containing 
the Brij 78 surfactant may overcome ABCB1-mediated drug 
resistance. By contrast, there are studies postulating that 
ABCB1 overexpression is a possible reason for resistance to 
nanoparticle-bound paclitaxel (11,12). Therefore, the role of 
Table V. IC50 values of cabozantinib and crizotinib in TCC-SUP, 
TCC-SUPrGEMCI20, TCC-SUPrVBL20, TCC-SUPCER2, 
TCC-SUPABCB1, T24, T24rGEMCI20, T24rVBL20, T24CER2 and 
T24ABCB1 cells.
 IC50 (resistance factor)
a, µM
 --------------------------------------------------------------------
Cell line Cabozantinib Crizotinib
TCC-SUP 5.08±0.17 0.90±0.02
TCC-SUPrGEMCI20 8.45±1.25 (1.66) 2.87±0.33 (3.12)
TCC-SUPrVBL20 6.67±0.21 (1.31) 1.55±0.15 (1.72)
TCC-SUPCER2 5.80±0.10 (1.14) 0.74±0.01 (0.82)
TCC-SUPABCB1 7.70±1.43 (1.52) 1.80±0.09 (2.00)
T24 11.02±0.27 6.16±0.74
T24rGEMCI20 11.64±1.68 (1.06) 3.33±0.34 (0.54)
T24rVBL20 7.16±0.09 (0.65) 1.50±0.13 (0.24)
T24CER2 10.21±0.04 (0.93) 3.54±0.31 (0.57)
T24ABCB1 8.91±0.63 (0.81) 5.32±0.21 (0.86)
a5HVLVWDQFHIDFWRU ,&50 of the drug in the resistant sub-line/IC50 of the 
drug in the parental cell line. Values are means ± standard deviations. 
IC50, half maximal inhibitory concentration.
Table IV. IC50 values of paclitaxel, nab-paclitaxel, gemcitabine and vinblastine in T24, T24
rGEMCI20, T24rVBL20, T24CER2 and 
T24ABCB1 cells in the presence of crizotinib.
 IC50 (sensitization factor)
a, ng/ml
 ------------------------------------------------------------------------------------------------------------------------------------------------------------------
Cell line Crizotinib, µM Paclitaxel Nab-paclitaxel Gemcitabine Vinblastine
T24 0 4.92±1.07 4.31±0.48 3.82±1.10 0.61±0.28
T24 0.5 3.31±0.47 (1.49) 2.54±0.33 (1.70) 3.03±0.05 (1.26) 0.86±0.30 (0.71)
T24 1.25 2.29±0.10 (2.15) 19.92±4.30 (0.22) 4.46±0.74 (0.86) 4.65±2.32 (0.13)
T24rGEMCI20 0 7.09±1.24 9.33±2.54 51.54±3.20 0.62±0.13
T24rGEMCI20 0.5 2.54±0.55 (2.79) 2.73±0.37 (3.42) 52.60±0.03 (0.98) 0.45±0.07 (1.38)
T24rGEMCI20 1.25 8.60±2.86 (0.82) 7.50±0.01 (1.24) 47.42±6.60 (1.09) 11.20±4.39 (0.06)
T24rVBL20 0 575.30±46.30 1,006.60±106.00 1.97±0.64 118.82±15.20
T24rVBL20 0.5 305.80±82.70 (1.88) 565.62±33.20 (1.78) 1.58±0.03 (1.25) 87.76±8.16 (1.35)
T24rVBL20 1.25 118.50±80.10 (4.85) 168.70±41.80 (5.96) 1.94±0.51 (1.02) 58.13±8.85 (2.04)
T24CER2 0 4.51±1.56 7.02±1.97 5.40±2.16 0.66±0.11
T24CER2 0.5 2.56±0.66 (1.76) 3.83±1.55 (1.83) 3.44±0.10 (1.57) 0.83±0.20 (0.80)
T24CER2 1.25 1.52±0.35 (2.97) 5.32±0.75 (1.32) 10.31±1.30 (0.52) 0.96±0.27 (0.69)
T24ABCB1 0 100.80±23.40 129.99±15.60 4.43±1.80 13.24±2.48
T24ABCB1 0.5 64.80±17.50 (1.56) 77.07±16.20 (1.69) 2.81±0.04 (1.58) 13.92±3.30 (0.95)
T24ABCB1 1.25 36.20±3.97 (2.78) 68.22±21.70 (1.91) 5.99±0.90 (0.74) 10.32±4.25 (1.28)
a6HQVLWL]DWLRQIDFWRU ,&50 of the drug in the tested cell line without cabozantinib/IC50 of the drug in the tested cell line plus cabozantinib. Values 
are means ± standard deviations. IC50, half maximal inhibitory concentration; nab, nanoparticle albumin-bound.
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ABCB1 as a resistance mechanism to nab-paclitaxel remains 
unclear (5).
In the present study, a well-established panel of urothelial 
cancer cell lines with acquired resistance to gemcitabine was 
used as a part of the standard chemotherapy of patients with 
metastasized urothelial bladder cancer (18). In addition, cell 
lines with acquired resistance to vinblastine, a well-known 
substrate of ABCB1 that forms part of the alternative bladder 
cancer chemotherapy regimen methotrexate, vinblastine, 
doxorubicin and cisplatin (MVAC) (27), were used. Further-
more, cell lines with stable ectopic expression of ABCB1 
were used to elucidate the resistance mechanisms against 
nab-paclitaxel treatment. ABCB1 overexpression and func-
tional drug transport were previously demonstrated in the 
T24rVBL20, TCC-SUPrGEMCI20 and TCC-SUPrVBL20 cell 
lines with acquired chemoresistance, and in the T24ABCB1 and 
TCC-SUPABCB1 cell lines with stable ectopic expression of 
ABCB1 (18).
Nano-sized drug carrier systems have been demonstrated WRFLUFXPYHQW$%&WUDQVSRUWHUPHGLDWHGGUXJHIÁX[28,29), DQGWKHLQFUHDVHGHIÀFDF\RIQDQRSDUWLFOHERXQGSDFOLWD[HOZDVH[SODLQHGE\DGHFUHDVHGHIÁX[UDWHWKURXJKWKHLQKL-
bition of ABCB1 (10). By contrast, in the cell line model 
of the present study, a similar cross-resistance profile in 
ABCB1-overexpressing cell lines to paclitaxel and nab-pacli-
taxel was demonstrated (Tables I-IV). Zhao et al (12) LGHQWLÀHGWKDWDQ16&/&FHOOOLQHZLWKDFTXLUHGUHVLVWDQFH
to nab-paclitaxel was also resistant to ABCB1 substrates. The 
authors suggested that the overexpression of ABCB1 serves 
an important role in resistance to nab-paclitaxel in NSCLC, 
similarly to the common resistance mechanism for pacli-
taxel (12). They hypothesized that paclitaxel, being the active 
component in nab-paclitaxel, is responsible for the develop-
ment of drug resistance (12). Additionally, they concluded 
that paclitaxel is likely to be dissociated from albumin inside 
the cell and pumped out by ABCB1 as a free molecule, as 
the albumin is too large to be transported by ABC drug 
pumps (12). Therefore, the reason for ABCB1-mediated 
resistance to nab-paclitaxel may be the aforementioned disso-
ciation of paclitaxel from albumin subsequent to endocytosis, 
and nab-paclitaxel may cause the same cytotoxicity to tumor 
cells as unbound paclitaxel (12,30). This would suggest that 
tumor cells in vitro are sensitive or resistant to nab-paclitaxel 
and paclitaxel at the same level.
Numerous studies have been conducted to develop inhibi-
tors for ABC transporters to circumvent ABCB1-associated 
resistance. At present, several clinical trials are ongoing to 
evaluate the clinical role of ABCB1 inhibitors to prevent drug 
resistance (31-34). However, none of the tested compounds 
had been approved for clinical use until 2010 (34). In the 
present study, the TKI crizotinib reversed ABCB1-mediated 
drug resistance of paclitaxel and nab-paclitaxel without 
changing Akt/pAkt expression. The phosphorylation of Akt 
and extracellular signal-related kinase (ERK) 1/2 are known 
downstream markers of crizotinib (19). These molecules may 
be used to test the targeted activity of crizotinib (19). The 
results of the present study are in accordance with the study 
of Zhou et al (33). In that study, the authors demonstrated that 
crizotinib reversed multidrug resistance in different cancer 
cell lines by inhibiting the function of ABCB1 without incur-ULQJVLJQLÀFDQWFKDQJHVWRWKHH[SUHVVLRQRI$NW(5.RU
c-MET (33). Additionally in the present study, the second 
tested TKI, cabozantinib, re-sensitized chemoresistant 
cancer cell lines to ABCB1 substrates without affecting 
the expression of downstream molecules. These results are 
consistent with the study of Xiang et al (20), who revealed 
that cabozantinib treatment in hepatocellular cancer cells UHYHUVHG$%&%PHGLDWHGFKHPRUHVLVWDQFHZLWKQRVLJQLÀ-
cant change to the levels of the downstream molecules Akt, 
ERK1/2 or MET. As promising overall response rates have 
been demonstrated for nab-paclitaxel treatment in patients 
with metastatic platinum-refractory urothelial cancer (7), a 
combination of nab-paclitaxel and cabozantinib or crizotinib 
should be clinically evaluated to avoid the development of 
resistance against nab-paclitaxel and to extend the antitu-
moral effect of the drug.
In the present study, the cytotoxic effects of vinblastine 
were demonstrated to be increased when vinblastine was 
administered in combination with cabozantinib. The Vinca 
alkaloid vinblastine binds to tubulin and inhibits the assembly 
of microtubules, similarly to the mechanisms of paclitaxel and 
nab-paclitaxel (35). Furthermore, ABCB1 serves a similar role 
in the development of vinblastine resistance (36). Vinblastine, 
as a part of the alternative bladder cancer chemotherapy 
regimen MVAC,LVDGPLQLVWHUHGDVÀUVWOLQHWKHUDS\RUVXEVH-
quent to the failure of gemcitabine/cisplatin treatment (27,37). 
Therefore, a combination of vinblastine with cabozantinib 
may be a reasonable option for the treatment of patients with 
Figure 2. Effect of cabazantinib and crizotinib treatment on Akt/pAkt expression. A representative western blot analysis of at least three independent experi-
ments in TCC-SUP, TCC-SUPrVBL20, TCC-SUPrGEMCI20, TCC-SUPCER2 and TCC-SUPABCB1 cell lines subsequent to treatment with 5 or 2.5 µM crizotinib FRPSDUHGZLWKXQWUHDWHGFHOOV7KHFHOOVZHUHO\VHGDQGSURWHLQVZHUHGHWHFWHGXVLQJVSHFLÀFDQWLERGLHVDJDLQVW$NWS$NW7DQGơ-actin. Akt, protein 
kinase B; p, phosphorylated.
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metastatic urothelial bladder cancer. However, additional 
in vivoVWXGLHVDUHUHTXLUHGWRHYDOXDWHWKHHIÀFDF\RIDFRPEL-
nation therapy of TKI with vinblastine.
In conclusion, resistance to nab-paclitaxel in ABC 
transporter-expressing urothelial cancer cells appears to be 
mediated by ABCB1. The data of the present study suggest 
that the previously identified beneficial clinical effects of 
nab-paclitaxel compared with those of paclitaxel are possibly 
due to improved pharmacokinetics and decreased systemic 
toxicity. In addition, ABCB1 inhibition by the small molecule 
inhibitors cabozantinib or crizotinib may improve clinical 
response to chemotherapy.
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